Latest News

Olfax Medical has been awarded a Peer Reviewed Medical Research Program (PRMRP) from the US Department of Defense to accelerate commercialization of a rapid, non-addictive treatment for headache disorders.

Olfax Medical has received a One NC Small Business Program award through the North Carolina Department of Commerce to support development of novel, nasally delivered therapeutics for treatment of neurological conditions.

Olfax Medical has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) to develop a novel, acute migraine therapy.

NCBiotech has named Olfax Medical one of North Carolina’s top-three life science technology startups. The announcement was made as part of the 2022 NC BIONEER Venture Challenge at Triad BioNight, a bi-annual celebration of the state’s life sciences community.

Olfax Medical, has been awarded a $54K grant from the NIH funded, DRIVEN Accelerator Hub to support development of Relaspen – a rapid, non-addictive migraine treatment for individuals of all ages.

Olfax Medical has been selected through competitive review as one of three companies into the 2021 DRIVEN Partnership Program.

Olfax Medical was selected from a record number of applicants across the state of North Carolina to participate in the 2021 Federal and State Technology (FAST) Partnership Program.  As part of the program, Olfax Medical is granted access to expert resources from Eva Garland Consulting to assist with submitting a competitive Phase I proposal to secure funding through the Small Business Innovation Research (SBIR) program and business advice from serial entrepreneurs and investors within the First Flight Venture Center.

Olfax Medical was selected from a pool of 99 applicants as a 2019 Asheville Impact Micro Grant award recipient.  In addition to receiving funding, Olfax Medical will receive support through Venture Asheville’s mentorship program (Elevate), connections to resource partners, and the potential for follow-on rounds of funding.